UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
DATE OF REPORT:
December 12, 2002
(Date of earliest event reported)
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
| DELAWARE (State or other jurisdiction of incorporation or organization) |
0-19731 (Commission File Number) |
94-3047598 (I.R.S. Employer Identification No.) |
||
333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA (Address of principal executive offices) |
||||
94404 (Zip Code) |
||||
(650) 574-3000 (Registrant's telephone number, including area code) |
||||
On December 12, 2002, Gilead Sciences, Inc. announced that it intends to raise approximately $300.0 million ($345.0 million if the initial purchaser's over-allotment option is exercised in full) through an offering of five-year notes that are convertible into shares of Gilead common stock. A press release relating to the notes is attached hereto as Exhibit 99.1.
Item 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GILEAD SCIENCES, INC. (registrant) |
||
/s/ JOHN F. MILLIGAN John F. Milligan Senior Vice President and Chief Financial Officer |
Date: December 12, 2002
3
| Exhibit Number |
Description |
|
|---|---|---|
| 99.1 | Press Release titled "Gilead to Raise $300 Million from Offering of Convertible Notes" dated December 12, 2002. |
4